Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms

European Journal of Clinical Pharmacology

Volumn 63, Issue 3, 2007, Pages 233-241

  Güzey, Cüneyt ^a,b   Scordo, Maria Gabriella ^c   Spina, Edoardo ^d,e   Landsem, Veslemøy Malm ^b   Spigset, Olav ^a,b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c UPPSALA UNIVERSITY   (Sweden)

^d UNIVERSITY OF MESSINA   (Italy)

^e IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Dopamine receptors; Dopamine transporter; Polymorphism; Serotonin receptors; Serotonin transporter

Indexed keywords

BIPERIDEN; CHLORPROMAZINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; ORPHENADRINE; PERPHENAZINE; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; THIORIDAZINE; TRIHEXYPHENIDYL; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG INDUCED DISEASE; DRUG SAFETY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TANDEM REPEAT; TARDIVE DYSKINESIA; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MINISATELLITE REPEATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE; SCHIZOPHRENIA; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33846907203     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0234-8     Document Type: Article

References (58)

1. Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JF, Sham P, Collier DA, Murray RM, Kerwin RW (2000) Pharmacogenetic prediction of clozapine response. Lancet 355:1615-1616
2. Ayd FJ Jr (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175:1054-1060
3. Baldessarini RJ (1985) Chemotherapy in Psychiatry. Harvard University Press, Cambridge
4. Basile VS, Özdemir V, Masellis M, Meltzer HY, Lieberman JA, Potkin SG, Macciardi FM, Petronis A, Kennedy JL (2001) Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 6:230-234
5. Caligiuri MP, Lacro JP, Jeste DV (1999) Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 19:322-328
6. Caligiuri MP, Lacro JP, Rockwell E, McAdams LA, Jeste DV (1997) Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 171:148-153
7. Chen CH, Wei FC, Koong FJ, Hsiao KJ (1997) Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol Psychiatry 41:827-829
8. de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ (2005) Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J Clin Psychopharmacol 25:448-456
9. Dewey SL, Smith GS, Logan J, Alexoff D, Ding YS, King P, Pappas N, Brodie JD, Ashby CR Jr (1995) Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis. J Neurosci 15:821-829
10. Dubertret C, Gorwood P, Gouya L, Deybach JC, Ades J (2001) Association and excess of transmission of a DRD2 haplotype in a sample of French schizophrenic patients. Schizophr Res 49:203-212
11. Eichhammer P, Albus M, Borrmann-Hassenbach M, Schoeler A, Putzhammer A, Frick U, Klein HE, Rohrmeier T (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 96:187-191
12. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J, Bondy B, Chen K, Shih JC, Knapp M, Propping P, Nothen MM (1996) Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 97:614-619
13. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S (2001) The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J 1:152-156
14. Gelernter J, Kranzler H, Cubells JF (1997) Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African-and European-American and Japanese populations and in alcohol-dependent subjects. Hum Genet 101:243-246
15. Goff DC, Henderson DC, Amico E (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. Am J Psychiatry 149:1189-1194
16. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O (1989) The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 45:778-785
17. Greenwood TA, Kelsoe JR (2003) Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82:511-520
18. Grevle L, Güzey C, Hadidi H, Brennersted R, Idle JR, Aasly J (2000) Allelic association between the DRD2 TaqI A polymorphism and Parkinson's disease. Mov Disord 15:1070-1074
19. Harvey L, Reid RE, Ma C, Knight PJ, Pfeifer TA, Grigliatti TA (2003) Human genetic variations in the 5HT2A receptor: a single nucleotide polymorphism identified with altered response to clozapine. Pharmacogenetics 13:107-118
20. Hazelwood LA, Sanders-Bush E (2004) His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol 66:1293-1300
21. Hedenmalm K, Güzey C, Dahl ML, Yue QY, Spigset O (2006) Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 26:192-197
22. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR (2000) A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47:643-649
23. Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J (2001) Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am J Med Genet 105:774-778
24. Kaiser R, Tremblay PB, Klufmoller F, Roots I, Brockmoller J (2002) Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia. Mol Psychiatry 7:695-705
25. Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 39:473-481
26. Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466-476
27. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
28. Khait VD, Huang YY, Zalsman G, Oquendo MA, Brent DA, Harkavy-Friedman JM, Mann JJ (2005) Association of serotonin 5-HT2A receptor binding and the T102C polymorphism in depressed and healthy Caucasian subjects. Neuropsychopharmacology 30:166-172
29. Kostrzewa RM, Reader TA, Descarries L (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J Neurochem 70:889-898
30. Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T (2000) Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transm 107:295-302
31. Lannfelt L, Sokoloff PMM, Pilon C, Giros B, Johnson E, Sedvall G, Schwartz JC (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigation psychiatric disorders. Psychiatric Gen 2:249-256
32. Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E (2004) Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 7:489-493
33. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, Aschauer HN, McCreadie RG, Ohlraun S, Ferrier N, Masellis M, Verga M, Scharfetter J, Rietschel M, Lovlie R, Levy UH, Meltzer HY, Kennedy JL, Steen VM, Macciardi F (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27:105-119
34. Lerer B, Segman RH, Tan EC, Basile VS, Cavallaro R, Aschauer HN, Strous R, Chong SA, Heresco-Levy U, Verga M, Scharfetter J, Meltzer HY, Kennedy JL, Macciardi F (2005) Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8:411-425
35. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527-1531
36. Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238-246
37. Mendlewicz J, Massat I, Souery D, Del-Favero J, Oruc L, Nothen MM, Blackwood D, Muir W, Battersby S, Lerer B, Segman RH, Kaneva R, Serretti A, Lilli R, Lorenzi C, Jakovljevic M, Ivezic S, Rietschel M, Milanova V, Van BC (2004) Serotonin transporter 5HTTLPR polymorphism and affective disorders: no evidence of association in a large European multicenter study. Eur J Hum Genet 12:377-382
38. Menza MA, Grossman N, Van HM, Cody R, Forman N (1991) Smoking and movement disorders in psychiatric patients. Biol Psychiatry 30:109-115
39. Mihara K, Suzuki A, Kondo T, Yasui-Furukori N, Ono S, Otani K, Kaneko S, Inoue Y (2001) Relationship between Taq1 A dopamine D2 receptor (DRD2) polymorphism and prolactin response to bromperidol. Am J Med Genet 105:271-274
40. Mill J, Asherson P, Craig I, D'Souza UM (2005) Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet 6:3
41. Miller GM, Madras BK (2002) Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol Psychiatry 7:44-55
42. Nakazono Y, Abe H, Murakami H, Koyabu N, Isaka Y, Nemoto Y, Murata S, Tsutsumi Y, Ohtani H, Sawada Y (2005) Association between neuroleptic drug-induced extrapyramidal symptoms and dopamine D2-receptor polymorphisms in Japanese schizophrenic patients. Int J Clin Pharmacol Ther 43:163-171
43. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Arch Gen Psychiatry 48:648-654
44. Oliveri RL, Annesi G, Zappia M, Civitelli D, De Marco EV, Pasqua AA, Annesi F, Spadafora P, Gambardella A, Nicoletti G, Branca D, Caracciolo M, Aguglia U, Quattrone A (2000) The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Mov Disord 15:127-131
45. Rissling I, Geller F, Bandmann O, Stiasny-Kolster K, Korner Y, Meindorfner C, Kruger HP, Oertel WH, Moller JC (2004) Dopamine receptor gene polymorphisms in Parkinson's disease patients reporting "sleep attacks". Mov Disord 19:1279-1284
46. Salokangas RK, Honkonen T, Stengard E, Koivisto AM, Hietala J (2006) Cigarette smoking in long-term schizophrenia. Eur Psychiatry 21(4):219-23
47. Schafer M, Rujescu D, Giegling I, Guntermann A, Erfurth A, Bondy B, Moller HJ (2001) Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene. Am J Psychiatry 158:802-804
48. Scordo MG, Spina E, Romeo P, Dahl ML, Bertilsson L, Johansson I, Sjoqvist F (2000) CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol 56:679-683
49. Segman RH, Heresco-Levy U, Finkel B, Goltser T, Shalem R, Schlafman M, Dorevitch A, Yakir A, Greenberg D, Lerner A, Lerer B (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6:225-229
50. Srivastava V, Varma PG, Prasad S, Semwal P, Nimgaonkar VL, Lerer B, Deshpande SN, Bk T (2006) Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet Genomics 16:111-117
51. Steen VM, Lovlie R, MacEwan T, McCreadie RG (1997) Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 2:139-145
52. Suzuki A, Kondo T, Otani K, Mihara K, Yasui-Furukori N, Sano A, Koshiro K, Kaneko S (2001) Association of the TaqI A polymorphism of the dopamine D(2) receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 158:1714-1716
53. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, Kaneko S (2000) The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics 10:335-341
54. Tan EK, Tan Y, Chai A, Tan C, Shen H, Lum SY, Fook-Cheong SM, Teoh ML, Yih Y, Wong MC, Zhao Y (2003) Dopamine D2 receptor TaqIA and TaqIB polymorphisms in Parkinson's disease. Mov Disord 18:593-595
55. Thompson J, Thomas N, Singleton A, Piggott M, Lloyd S, Perry EK, Morris CM, Perry RH, Ferrier IN, Court JA (1997) D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7:479-484
56. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14:1104-1106
57. Wang J, Liu ZL, Chen B (2001) Association study of dopamine D2, D3 receptor gene polymorphisms with motor fluctuations in PD. Neurology 56:1757-1759
58. Young RM, Lawford BR, Barnes M, Burton SC, Ritchie T, Ward WK, Noble EP (2004) Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 185:147-151